Protocol Ledger

NCT06014190 · Phase II · RECRUITING

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Interventional Phase II clinical trial protocol NCT06014190 sponsored by Hansoh BioMedical R&D Company in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-18 Enrollment: 460 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06014190
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)460 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06014190
Protocol FieldVerified Registry Value
NCT IdentifierNCT06014190
Consolidated Lead SponsorHansoh BioMedical R&D Company
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment460 participants (ESTIMATED)
Registered Start Date2023-12-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06014190
Hospital Research SiteLocationSite Profile
Anhui Provincial Cancer HospitalHefei, ChinaOpen Hospital Dossier ->
Peking University Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Chongqing University Cancer HospitalChongqing, ChinaOpen Hospital Dossier ->
Fujian Cancer HospitalFuzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI